Pertuzumab, trastuzumab, and hyaluronidase-zzxf (Phesgo™, Genentech) injection for subcutaneous use will be issued a permanent J-Code that can be used starting January 1, 2021.
This single code (J9316) is to be used for all PHESGO patients and dosage strengths.
Indications
Early Breast Cancer
Phesgo™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is indicated for use in combination with chemotherapy for
-
The neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node-positive) as part of a complete treatment regimen for early breast cancer (EBC); and
-
The adjuvant treatment of adult patients with HER2-positive early breast cancer (EBC) at high risk of recurrence.
Select patients for therapy based on an FDA-approved companion diagnostic test.
Metastatic Breast Cancer
Phesgo™ is indicated for use in combination with docetaxel for the treatment of adult patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
Select patients for therapy based on an FDA-approved companion diagnostic test.
See prescribing information.
Posted on 11/19/2020